Literature DB >> 23580528

Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Elizabeth B Wilson1, Douglas H Yamada, Heidi Elsaesser, Jonathan Herskovitz, Jane Deng, Genhong Cheng, Bruce J Aronow, Christopher L Karp, David G Brooks.   

Abstract

Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580528      PMCID: PMC3704950          DOI: 10.1126/science.1235208

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  28 in total

1.  Interleukin-10 determines viral clearance or persistence in vivo.

Authors:  David G Brooks; Matthew J Trifilo; Kurt H Edelmann; Luc Teyton; Dorian B McGavern; Michael B A Oldstone
Journal:  Nat Med       Date:  2006-10-15       Impact factor: 53.440

2.  Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus.

Authors:  Eirini I Rigopoulou; William G H Abbott; Philip Haigh; Nikolai V Naoumov
Journal:  Clin Immunol       Date:  2005-10       Impact factor: 3.969

3.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

4.  Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys.

Authors:  Steven E Bosinger; Qingsheng Li; Shari N Gordon; Nichole R Klatt; Lijie Duan; Luoling Xu; Nicholas Francella; Abubaker Sidahmed; Anthony J Smith; Elizabeth M Cramer; Ming Zeng; David Masopust; John V Carlis; Longsi Ran; Thomas H Vanderford; Mirko Paiardini; R Benjamin Isett; Don A Baldwin; James G Else; Silvija I Staprans; Guido Silvestri; Ashley T Haase; David J Kelvin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

5.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

6.  Nonredundant roles for B cell-derived IL-10 in immune counter-regulation.

Authors:  Rajat Madan; Filiz Demircik; Sangeetha Surianarayanan; Jessica L Allen; Senad Divanovic; Aurelien Trompette; Nir Yogev; Yuanyuan Gu; Marat Khodoun; David Hildeman; Nicholas Boespflug; Mariela B Fogolin; Lothar Gröbe; Marina Greweling; Fred D Finkelman; Rhonda Cardin; Markus Mohrs; Werner Müller; Ari Waisman; Axel Roers; Christopher L Karp
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

7.  Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection.

Authors:  Qingsheng Li; Pamela J Skinner; Sang-Jun Ha; Lijie Duan; Teresa L Mattila; Aaron Hage; Cara White; Daniel L Barber; Leigh O'Mara; Peter J Southern; Cavan S Reilly; John V Carlis; Christopher J Miller; Rafi Ahmed; Ashley T Haase
Journal:  Science       Date:  2009-03-27       Impact factor: 47.728

8.  Interferon signaling and treatment outcome in chronic hepatitis C.

Authors:  Magdalena Sarasin-Filipowicz; Edward J Oakeley; Francois H T Duong; Verena Christen; Luigi Terracciano; Witold Filipowicz; Markus H Heim
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-08       Impact factor: 11.205

9.  IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells.

Authors:  Mark A Brockman; Douglas S Kwon; Daniel P Tighe; David F Pavlik; Pamela C Rosato; Jennifer Sela; Filippos Porichis; Sylvie Le Gall; Michael T Waring; Kristin Moss; Heiko Jessen; Florencia Pereyra; Daniel G Kavanagh; Bruce D Walker; Daniel E Kaufmann
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

10.  Resolution of a chronic viral infection after interleukin-10 receptor blockade.

Authors:  Mette Ejrnaes; Christophe M Filippi; Marianne M Martinic; Eleanor M Ling; Lisa M Togher; Shane Crotty; Matthias G von Herrath
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

View more
  372 in total

1.  Therapeutic depletion of natural killer cells controls persistent infection.

Authors:  Stephen N Waggoner; Keith A Daniels; Raymond M Welsh
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 2.  Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice.

Authors:  Lishan Su
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

Review 3.  Innate and Adaptive Immune Regulation During Chronic Viral Infections.

Authors:  Elina I Zuniga; Monica Macal; Gavin M Lewis; James A Harker
Journal:  Annu Rev Virol       Date:  2015-09-02       Impact factor: 10.431

Review 4.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

Review 5.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

6.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

Authors:  Xuanming Yang; Xunmin Zhang; May Lynne Fu; Ralph R Weichselbaum; Thomas F Gajewski; Yajun Guo; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

7.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 8.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

9.  Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Authors:  Magar Ghazarian; Xavier S Revelo; Mark K Nøhr; Helen Luck; Kejing Zeng; Helena Lei; Sue Tsai; Stephanie A Schroer; Yoo Jin Park; Melissa Hui Yen Chng; Lei Shen; June Ann D'Angelo; Peter Horton; William C Chapman; Diane Brockmeier; Minna Woo; Edgar G Engleman; Oyedele Adeyi; Naoto Hirano; Tianru Jin; Adam J Gehring; Shawn Winer; Daniel A Winer
Journal:  Sci Immunol       Date:  2017-04-21

10.  Exacerbated Apoptosis of Cells Infected with Infectious Bursal Disease Virus upon Exposure to Interferon Alpha.

Authors:  Liliana L Cubas-Gaona; Elisabet Diaz-Beneitez; Marina Ciscar; José F Rodríguez; Dolores Rodríguez
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.